FDA approves Pasatru to reduce lesions, flare-ups in fibrodysplasia ossificans progressiva

The FDA approved a novel therapy for reducing the formation of heterotopic ossification lesions and flare-ups for adults with fibrodysplasia ossificans progressiva, according to an industry press release.Garetosmab-grts (Pasatru, Regeneron) is a monoclonal antibody administered through IV infusion. According to Regeneron, the therapy is the first approved by the FDA for reducing new heterotopic